13. Stamceltransplantatie

go back to reference Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813-26.PubMedCrossRef Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813-26.PubMedCrossRef

go back to reference Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med. 1997;336:897-950.PubMedCrossRef Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med. 1997;336:897-950.PubMedCrossRef

go back to reference Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med. 1991;324:667-74.PubMedCrossRef Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med. 1991;324:667-74.PubMedCrossRef

go back to reference Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Bone Marrow Transplant. 2005;11:945-56.CrossRef Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Bone Marrow Transplant. 2005;11:945-56.CrossRef

go back to reference Gratwohl A. The EBMT risk score. Bone Marrow Transplant. 2012;47:749-56.PubMedCrossRef Gratwohl A. The EBMT risk score. Bone Marrow Transplant. 2012;47:749-56.PubMedCrossRef

go back to reference Huisman C, Visser O, Verdonck LF. Late complicaties na allogene stamceltransplantaties bij volwassenen. Ned Tijdschr Hematol. 2010;7:188-97. Huisman C, Visser O, Verdonck LF. Late complicaties na allogene stamceltransplantaties bij volwassenen. Ned Tijdschr Hematol. 2010;7:188-97.

go back to reference Huisman C. Richtlijn Aanbevolen lange termijn follow-up na allogene hematopoïetische stamceltransplantatie. http://www.hovon.nl/werkgroepen/studiewerkgroepen/stamceltransplantatie.html Huisman C. Richtlijn Aanbevolen lange termijn follow-up na allogene hematopoïetische stamceltransplantatie. http://​www.​hovon.​nl/​werkgroepen/​studiewerkgroepe​n/​stamceltransplan​tatie.​html

go back to reference Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia in allogeneic chimeras. Blood. 2004;103:767-76.PubMedCrossRef Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia in allogeneic chimeras. Blood. 2004;103:767-76.PubMedCrossRef

go back to reference Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Bone Marrow Transplant. 2012;47:337-41.PubMedCrossRef Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Bone Marrow Transplant. 2012;47:337-41.PubMedCrossRef

go back to reference Niederwieser D, Maris M, Shizuru JA, et al. Low-dose total body-irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood. 2003;101:1620-9.PubMedCrossRef Niederwieser D, Maris M, Shizuru JA, et al. Low-dose total body-irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood. 2003;101:1620-9.PubMedCrossRef

go back to reference Passweg JR, Baldomero H, Gratwohl A, et al. The EBMT activity survey: 1990-2010. Bone Marrow Transplant. 2012;47:906-23.PubMedCrossRef Passweg JR, Baldomero H, Gratwohl A, et al. The EBMT activity survey: 1990-2010. Bone Marrow Transplant. 2012;47:906-23.PubMedCrossRef